Lifecore Biomedical, Inc.

NasdaqGS:LFCR 주식 리포트

시가총액: US$190.9m

Lifecore Biomedical 향후 성장

Future 기준 점검 0/6

Lifecore Biomedical은 연간 수입과 매출이 각각 0.9%와 11.5% 증가할 것으로 예상되고 EPS는 연간 1.7%만큼 증가할 것으로 예상됩니다.

핵심 정보

0.9%

이익 성장률

1.72%

EPS 성장률

Life Sciences 이익 성장16.9%
매출 성장률11.5%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트16 Jun 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Jun 30

Is Now An Opportune Moment To Examine Lifecore Biomedical, Inc. (NASDAQ:LFCR)?

Lifecore Biomedical, Inc. ( NASDAQ:LFCR ), is not the largest company out there, but it received a lot of attention...
내러티브 업데이트 • Jun 26

LFCR: New Pharma Agreements Will Shape A Measured Outlook Ahead

Lifecore Biomedical’s analyst price target has moved to $6.50, a $0.50 increase that analysts link to recent agreements with global pharmaceutical partners, as well as greater confidence in the company’s ability to expand its clinical reach and execute on its plans. Analyst Commentary Recent Street research on Lifecore Biomedical centers on the updated US$6.50 price target, which is tied to new agreements with global pharmaceutical partners and increased confidence in the company’s ability to carry out its plans.
내러티브 업데이트 • Jun 11

LFCR: CDMO Site Transfers And 2028 Ramps Will Drive Long Term Upside

Narrative Update on Lifecore Biomedical The analyst price target for Lifecore Biomedical has been reset to $5, reflecting a balance between a $5.50 target tied to expectations for a later breakout year and a $5 target that factors in softer FY26 guidance and delayed commercial ramps, which analysts generally view as timing related rather than a shift in the long term opportunity. Analyst Commentary Recent Street research on Lifecore Biomedical reflects a mix of optimism about the long term setup and caution around the near term execution and guidance.
내러티브 업데이트 • May 28

LFCR: CDMO Site Transfers And 2028 Ramps Will Support Future Upside

Narrative Update: Lifecore Biomedical Analysts have adjusted their average price target for Lifecore Biomedical toward $5 to $5.50, reflecting mixed recent research in which one firm lifted its target by $0.50 while another reduced its target by $3.50. The firms cited the timing of commercial ramps and a slightly later potential breakout year as key drivers.
내러티브 업데이트 • May 01

LFCR: CDMO Site Transfers And 2028 Commercial Ramps Will Drive Upside

Narrative update on Lifecore Biomedical The updated analyst price target for Lifecore Biomedical moves to $6.67 from $6.50. Analysts point to slightly higher modeled fair value, a modestly adjusted discount rate, incremental changes to revenue growth and margin assumptions, and a higher future P/E multiple following recent target revisions and rating changes.
내러티브 업데이트 • Apr 16

LFCR: CDMO Site Transfers And 2028 Pipeline Ramps Will Drive Upside

Narrative Update: Lifecore Biomedical The analyst price target on Lifecore Biomedical has shifted to a range centered around $5 to $5.50, reflecting reactions to softer FY26 guidance and delayed commercial ramps, while analysts generally frame these changes as timing related and continue to describe long term potential tied to future program wins and site transfers. Analyst Commentary Recent research shows a mix of optimism and caution around Lifecore Biomedical, with price targets clustering around the mid single digits and views that recent guidance reflects timing shifts rather than a change in the longer term opportunity.
내러티브 업데이트 • Apr 01

LFCR: CDMO Site Transfers And Late Stage Pipeline Will Drive Future Upside

Narrative Update: Lifecore Biomedical Analysts have reset Lifecore Biomedical’s price expectations into a tighter band, with targets moving from $8.50 to a range of about $5 to $5.50 as they factor in pushed out commercial ramps and FY26 guidance that came in below expectations, while still viewing the long term opportunity as intact. Analyst Commentary Recent research shows a mix of optimism and caution around Lifecore Biomedical, with price targets reset into a US$5 to US$5.50 range and views that focus on timing of growth rather than the existence of the opportunity itself.
내러티브 업데이트 • Mar 18

LFCR: Delayed Commercial Ramps And CDMO Wins Will Drive Long Term Upside

Narrative Update: Lifecore Biomedical The analyst price target for Lifecore Biomedical has shifted lower, with recent cuts to around the $5 to $5.50 range. This reflects updated views on timing for commercial ramps and FY26 expectations, even as analysts continue to reference the long term opportunity.
분석 기사 • Jan 20

Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity

You may think that with a price-to-sales (or "P/S") ratio of 2.4x Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) is a stock...
Seeking Alpha • Jan 14

Lifecore Biomedical: Wins Should Blow Previous 'New Business' Estimates Out Of The Water

Summary Lifecore Biomedical has excess capacity in a market where there is a global shortage of capacity, demand is growing, and new supply cannot be quickly or effectively built. LFCR is a business with real competitive advantages that is executing at a very high level, where the stock has solid downside protection, and earnings power is growing. LFCR is well on their way to $100M in EBITDA versus a current enterprise value of approximately $400M where a 16x multiple would be conservative here. Lifecore Biomedical experienced fantastic execution toward increasing capacity utilization, and it seems as if the necessary elements of earnings power improvement and a re-rating are already in place. Read the full article on Seeking Alpha
내러티브 업데이트 • Jan 08

LFCR: New Index Inclusion And CDMO Agreements Will Support Balanced Outlook

Analysts now place a neutral US$8.75 price target on Lifecore Biomedical, with the change supported by updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors reflect a slightly more cautious yet still constructive outlook on the shares.
내러티브 업데이트 • Dec 21

LFCR: New Manufacturing Agreements Will Support Steadier Outlook With Balanced Prospects

Analysts have modestly revised their price target for Lifecore Biomedical to about $8.75 per share, citing slightly improved long term profit margin assumptions and a marginally lower discount rate that together support a steadier valuation outlook. What's in the News Lifecore signed a CDMO master services agreement with a new large global pharmaceutical customer to transfer commercial supply of an injectable product from overseas facilities to Lifecore, with potential for the partner to become one of its top five commercial customers (Key Developments).
내러티브 업데이트 • Dec 07

LFCR: New Supply And Services Agreements Will Drive Shares Higher

Analysts have modestly raised their price target on Lifecore Biomedical to $8.75, reflecting slightly improved discount rate and forward valuation assumptions even as profit margin expectations edge lower. What's in the News Lifecore Biomedical affirmed its transition period 2025 guidance, projecting revenue of approximately $74 million to $76 million and a net loss between $18.4 million and $16.4 million (company guidance filing).
내러티브 업데이트 • Nov 23

LFCR: New Program Wins Will Drive Shares Higher Amid Pipeline Transition

Analysts have kept their price target for Lifecore Biomedical steady at $8.75, citing a need for new program wins or contractual step-ups to drive meaningful valuation expansion as the company shifts toward faster-growing markets. Analyst Commentary Recent commentary from the Street highlights both optimism and caution regarding Lifecore Biomedical's outlook.
내러티브 업데이트 • Nov 06

LFCR: Future Program Wins Will Drive Upside As Pipeline Expands

Analysts have lowered their fair value estimate for Lifecore Biomedical from $10.00 to $8.75 per share. They cited moderated growth assumptions and the need for additional program wins to drive valuation expansion.
분석 기사 • Jul 18

Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • May 02

A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price

With a price-to-sales (or "P/S") ratio of 1.9x Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) may be sending bullish signals...
Seeking Alpha • Mar 03

Lifecore Biomedical: We Are Not Playing To Make 5% Or 10% Here

Summary Lifecore Biomedical can triple production without additional capital, driven by increased volumes, cost containment, and potential new contracts, boosting EBITDA margins from 15% to 25%+. Alcon's contractual minimum volume step-ups, estimated at $25M medium-term and $50M long-term, will significantly drive Lifecore's revenue growth. New CEO Paul Josephs' business development experience and strategic investments position Lifecore for substantial margin improvement and potential multiple expansion. Simple math suggests Lifecore's share price could rise from sub-$7 to $20, with potential for higher multiples and EBITDA margins, aiming for significant returns. Read the full article on Seeking Alpha
User avatar
새로운 내러티브 • Jan 26

Over 50 New Opportunities Expected From Business Development Expansion

Expanding business development and operational capacity is expected to drive revenue growth by broadening the customer base and enhancing earning potential.
Seeking Alpha • Dec 01

Lifecore Biomedical: An Interesting CDMO Pure Play

Summary Lifecore, a leading CDMO, specializes in sterile injectable pharmaceuticals and is poised to benefit from the growing CDMO market and potential GLP-1 opportunities. The company is doubling production capacity, enhancing financial performance, and attracting new customers with advanced technology and strategic investments. Despite a challenging Q1, Lifecore anticipates significant revenue growth and improved EBITDA in H2 FY25, driven by increased capacity utilization and cost management. With strong market tailwinds, experienced management, and promising financial outlook, Lifecore shares are rated a buy under $7. Read the full article on Seeking Alpha
분석 기사 • Nov 26

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward

Despite an already strong run, Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) shares have been powering on, with a gain of...
Seeking Alpha • Nov 12

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

Summary Lifecore has a new CEO, who has turned around three previous CDMOs, as well as a new CFO who was the CFO for another CDMO that was acquired. Lifecore now operates at less than 35% utilization, meaning that it can almost triple revenue with virtually no additional capital required. Margins should improve as volumes increase/capacity is utilized, but, even without growth, there is opportunity on the cost side. Read the full article on Seeking Alpha
Seeking Alpha • Jun 24

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Summary Lifecore Biomedical's strategic review process ended in March 2024 with no sale transaction materializing, leaving shareholders with uncertain prospects. The company, specializing in biomaterials for pharmaceutical and medical sectors, faces financial distress risk due to high leverage and cyclical sector challenges. A fair equity value of $6 per share, with a 20% upside, is suggested based on a comparable transaction, but risks including debt, leverage, and sector uncertainty jeopardize this potential upside. Read the full article on Seeking Alpha
Seeking Alpha • Apr 20

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Summary In our FY 2023 letter, we noted our less-than-ideal experience with merger-arbitrage strategies, with Lifecore Biomedical being the sole remaining investment of this nature in the portfolio. We bought more shares at $4.8 per share to bring Lifecore back to a 3% position. Lifecore is increasing capacity and most of this capacity is already paid for, potentially leading to a surge in free cash flow. Read the full article on Seeking Alpha
분석 기사 • Jun 30

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Oct 06

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Landec press release (NASDAQ:LNDC): Q1 Non-GAAP EPS of -$0.32. Revenue of $43.35M (+4.1% Y/Y). Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year period Lifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year period Consolidated adjusted EBITDA of $(1.1) million, compared to $2.5 million in the prior year period FISCAL 2023 OUTLOOK:The Company is reiterating its full year fiscal 2023 guidance for its Lifecore and Corporate segments. Lifecore segment revenue: range of $122 million to $126 million (+12% to +15%) Lifecore segment adjusted EBITDA: range of $31.0 million to $32.5 million (+7% to +12%) Other segment (corporate expense): range of ($7.0) million to ($7.5) million Consolidated adjusted EBITDA: range of $23.5 million to $25.5 million
Seeking Alpha • Sep 09

Landec receives Nasdaq's notification on delayed annual report filing

Landec (NASDAQ:LNDC) stated Friday that it has been notified by Nasdaq for not in compliance with exchange's listing rules as the company failed to file its annual report for the year ended May 29, 2022. Source: Press Release

이익 및 매출 성장 예측

NasdaqGS:LFCR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/2028159-4511N/A2
12/31/2027130-379245
12/31/2026122-398165
12/31/2025129-35613N/A
5/25/2025129-44-140N/A
2/23/2025130-49-113N/A
11/24/2024131-17-140N/A
8/25/20241286-97N/A
5/26/20241289-180N/A
2/25/2024122-21-34-11N/A
11/26/2023112-47-45-21N/A
8/27/2023104-70-48-25N/A
5/28/2023103-64-39-17N/A
2/26/202393-31-41-16N/A
11/27/2022104-27-46-22N/A
8/28/202293-15-50-25N/A
5/29/2022111-15-53-23N/A
2/27/2022135-12-49-18N/A
11/28/2021142-7-37-8N/A
8/29/202178-6-28-1N/A
5/30/2021101-23-916N/A
2/28/2021283-24-18-2N/A
11/29/2020391-34-216N/A
8/30/2020587-44-165N/A
5/31/2020160-22-44-17N/A
2/23/2020587-23-39-6N/A
11/24/2019590-10N/A-4N/A
8/25/2019572-3N/A8N/A
5/26/20195582N/A16N/A
2/24/20195468N/A17N/A
11/25/201853523N/A18N/A
8/26/201853324N/A19N/A
5/27/201852426N/A20N/A
2/25/201844821N/A27N/A
11/26/20174408N/A31N/A
8/27/20174539N/A27N/A
5/28/201747010N/A30N/A
2/26/201754013N/A39N/A
11/27/2016534-12N/A25N/A
8/28/2016538-11N/A30N/A
5/29/2016477-12N/A21N/A
2/28/2016540-12N/A19N/A
11/29/201554913N/A25N/A
8/30/201554114N/A20N/A

애널리스트 향후 성장 전망

수입 대 저축률: LFCR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: LFCR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: LFCR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: LFCR 의 수익(연간 11.5%)이 US 시장(연간 12.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: LFCR 의 수익(연간 11.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: LFCR의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/07/05 21:04
종가2026/07/02 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Lifecore Biomedical, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Michael PetuskyBarrington Research Associates, Inc.
Matthew HewittCraig-Hallum Capital Group LLC
Brian HollandD.A. Davidson & Co.